Next Article in Journal
Mini-Review: Challenges in Newborn Screening for Urea Cycle Disorders
Previous Article in Journal
The Story of Biotinidase Deficiency and Its Introduction into Newborn Screening: The Role of Serendipity
Article Menu

Export Article

Open AccessReview
Int. J. Neonatal Screen. 2015, 1(1), 13-26; https://doi.org/10.3390/ijns1010013

The Newborn Screening Quality Assurance Program at the Centers for Disease Control and Prevention: Thirty-Five Year Experience Assuring Newborn Screening Laboratory Quality

Newborn Screening and Molecular Biology Branch, Division of Laboratory Sciences, National Center for Environmental Health, US Centers for Disease Control and Prevention, 4770 Buford Highway, NE, Mail Stop F-19, Atlanta, GA 30341, USA
These authors contributed equally to this work.
*
Author to whom correspondence should be addressed.
Academic Editor: Ralph Fingerhut
Received: 25 February 2015 / Revised: 23 March 2015 / Accepted: 27 March 2015 / Published: 17 April 2015
View Full-Text   |   Download PDF [453 KB, uploaded 17 April 2015]   |  

Abstract

Newborn screening is the largest genetic testing effort in the United States and is considered one of the ten great public health achievements during the first 10 years of the 21st century. For over 35 years, the Newborn Screening Quality Assurance Program (NSQAP) at the US Centers for Disease Control and Prevention has helped NBS laboratories ensure that their testing does not delay diagnosis, minimizes false-positive reports, and sustains high-quality testing performance. It is a multi-component program that provides comprehensive quality assurance services for dried blood spot testing. The NSQAP, the Biochemical Mass Spectrometry Laboratory (BMSL), the Molecular Quality Improvement Program (MQIP) and the Newborn Screening Translation Research Initiative (NSTRI), aid screening laboratories achieve technical proficiency and maintain confidence in their performance while processing large volumes of specimens daily. The accuracy of screening tests could be the difference between life and death for many babies; in other instances, identifying newborns with a disorder means that they can be treated and thus avoid life-long disability or severe cognitive impairment. Thousands of newborns and their families have benefited from reliable and accurate testing that has been accomplished by a network of screening laboratories and the NSQAP, BMSL, MQIP and NSTRI. View Full-Text
Keywords: newborn screening; quality assurance; dried blood spots; Newborn Screening Quality Assurance Program newborn screening; quality assurance; dried blood spots; Newborn Screening Quality Assurance Program
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

De Jesús, V.R.; Mei, J.V.; Cordovado, S.K.; Cuthbert, C.D. The Newborn Screening Quality Assurance Program at the Centers for Disease Control and Prevention: Thirty-Five Year Experience Assuring Newborn Screening Laboratory Quality. Int. J. Neonatal Screen. 2015, 1, 13-26.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Int. J. Neonatal Screen. EISSN 2409-515X Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top